UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/587,512	11/08/2007	Justin Hanes	JHUC-P01-021	3582
28120 ROPES & GRA	7590 03/04/201 XY LLP	EXAMINER		
PATENT DOCKETING 39/41			SGAGIAS, MAGDALENE K	
ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624			ART UNIT	PAPER NUMBER
			1632	
			MAIL DATE	DELIVERY MODE
			03/04/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Occurrence	10/587,512	HANES ET AL.				
Office Action Summary	Examiner	Art Unit				
	Magdalene K. Sgagias	1632				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 15 De	ecember 2009.					
· <u> </u>						
· _	· · · · · · · · · · · · · · · · · · ·					
•	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-25</u> is/are pending in the application.						
,	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
· · · · · · · · · · · · · · · · · · ·	☐ Claim(s) is are objected to: ☐ Claim(s) <u>1-2, 5-10, 12-13 and 17-22</u> are subject to restriction and/or election requirement.					
Application Papers		•				
·· _						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ☐ Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application						
Paper No(s)/Mail Date						

DETAILED ACTION

Claims 1-25 are pending.

Applicant's election of group I, claims 1-2, 5-10, 12-13 and 17-22 is acknowledged.

Upon further consideration an election of species restriction is necessitated.

Election of Species

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Applicant is required to elect a single polymer core as for example is cited in claim 5: polymer is a poly(D,L-lactic-co-glycolic) acid, or polyethylenimine, or dioleyltrimethyaimoniumpropane/dioleyl-sn-glycerolphosphoethanolamine, or poly(anhydrides), or a polymer formed from clinically approved monomers.

Applicant is required to elect a single clinically approved monomer: sebacic acid, 1,3-bis(carboxyphenoxy)propane, or PEG as cited in claim 6.

Applicant is required to elect a single bioactive agent: a single therpaeutic agent or a single imaging agent as cited in claim 7.

If Applicant elects a therapeutic agent applicant is required to elect a single therapeutic agent: DNA, an RNA, a small molecule, a peptidomimetic, a protein.

If Applicant elects an imaging agent Applicant is required to elect a diagnostic agent or a detectable label.

Applicant is required to elect a single species of surface altering agent for claim 1 and its depended claims as cited in [009] of specification: anionic protein (e.g., serum albumin), nucleic acids, surfactants such as cationic surfactants (e.g., dimethyldioctadecyl-ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), polyethylene glycol, mucolytic agents, or other non-mucoadhesive agents. Certain agents, e.g., cyclodextrin, may form inclusion complexes with other molecules and can be used to form attachments to additional moieties and facilitate the functionalization of the particle surface and/or the attached molecules or moieties as cited in [009] of specification.

Claim 12 contains an adjuvant. Applicant is required to elect a single adjuvant as cited in [0041] of specification: radiosensitizers, transfection-enhancing agents, chemotactic agents or chemoattractants, peptides that modulate cell adhesion or cell mobility, cell permeabilizing agents, vaccine potentiators, inhibitors of multidrug resistance or efflux pumps.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 10/587,512 Page 4

Art Unit: 1632

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Magdalene K. Sgagias whose telephone number is (571)272-3305. The

examiner can normally be reached on Monday through Friday from 9 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Paras Peter can be reached on 571-272-4517. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you

would like assistance from a USPTO Customer Service Representative or access to the

automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Magdalene K. Sgagias, Ph.D.

Art Unit 1632

/Anne-Marie Falk/

Anne-Marie Falk, Ph.D.

Primary Examiner, Art Unit 1632